Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 5071-5080 Newer>

The Motley Fool January 3, 2005 Steven Mallas	Disney's Global Magic Disney wants to promote its parks through a fresh global campaign that also highlights Disneyland's 50th anniversary. Its stock might be heading in an upward trajectory, but it could just as easily falter.
The Motley Fool January 3, 2005 W.D. Crotty	Weighing Six Flags Before you think you have found a $5.50-a-share gem of a stock, consider that Standard & Poor's lowered Six Flags' already-junk status credit rating in November 2004.
The Motley Fool January 3, 2005 Rich Smith	No News Is Great News Microcaps are volatile; for the patient investor, that can be a good thing.
The Motley Fool January 3, 2005 Alyce Lomax	Blogs Booming? Although investors who have taken stock in newspapers and other media companies ought to keep a careful eye on the trend, for the time being, blogging itself is still an area where nobody's making much money.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool January 3, 2005 Jeff Hwang	Kmart Shows Operational Progress The same-store sales decline slows in November and December, and net income increases.
The Motley Fool January 3, 2005 Rich Smith	Talk Is Still Cheap For Q4, Talk America's (a provider of bundled local and long-distance calling services) holding the line with guidance of about $125 million in revenues, and earnings of roughly $11 million, or about $0.41 per share.
The Motley Fool January 3, 2005 Seth Jayson	Wal-Mart Sheds Sandbags No big surprise: Wal-Mart just beat its pessimistic forecasts, again.
The Motley Fool January 3, 2005 Rich Duprey	There's No Accounting for Goodyear The world's largest tire maker delays filing annual financial reports -- again.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
<Older 5071-5080 Newer> Return to current articles.